Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
MIL60 与贝伐单抗治疗晚期或复发性非鳞状非小细胞肺癌的疗效和安全性比较：一项 3 期随机双盲研究
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2021.101187
Wan, Rui; Dong, Xiaorong; Chen, Qun; Yu, Yan; Yang, Shujun; Zhang, Xiaochun; Zhang, Guojun; Pan, Yueyin; Sun, Sanyuan; Zhou, Chengzhi; Hong, Wei; Zhao, Hui; Yang, Lei; Huang, Linian; Wu, Rong; Zang, Aimin; Ma, Rui; Wu, Lin; Lv, Dongqing; Fu, Xiuhua; Han, Jianguo; Li, Wenxin; Duan, Jianchun; Wang, Kai; Jiang, Ou; Chen, Yinglan; Guo, Zhongliang; Gao, Hongjun; Wen, Juyi; Wang, Shubin; Zhao, Enfeng; Li, Gaofeng; Yue, Lu; Liang, Li; Zeng, Aiping; Wang, Xiaoshan; Zhu, Yuxi; Pan, Hongming; Dai, Zhaoxia; Feng, Weineng; Zhao, Guofang; Lin, Chuan; Li, Chong; Li, Na; Bao, Yangyi; Li, Yinyin; Su, Yanjun; Zhao, Min; Fang, Haohui; Zhu, Yulong; Zhang, Yu; Ding, Lieming; Wang, Yang; Yuan, Xiaobin; Wang, Jie
